¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"converting enzyme inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ƯÀ̼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • brancher enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • constitutive enzyme
    ±âº»±¸¼ºÈ¿¼Ò
  • cytosolic enzyme
    ¼¼Æ÷¾×È¿¼Ò
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò, Å»ºÐÁöÈ¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protease inhibitor
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ¼±ÅÃÀû¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤¹ý
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò¸é¿ªÀÌÀû¹ý, È¿¼Ò¿¬°ü¸é¿ªÀü±âÀü´ÞÁ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • reductase, 5-alpha-reductase inhibitor
    5a-ȯ¿øÈ¿¼Ò¾ïÁ¦Á¦(¡­ü½êªý£áÈåäð¤ð¥),5a-¸®´öÅ×À̽º¾ïÁ¦Á¦(¡­åäð¤ð¥)
  • ELISA => enzyme-linked immunosorbent assay
    ¿¤¶óÀÌÀÚ
  • EMMIA => enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • competitive inhibitor
    °æÀïÀû ¾ïÁ¦¹°.»ýÈ­°æÇÕÀû ÀúÇØ(ÌæùêîÜîÁúªð¥).
  • competitive inhibitor
    [»ýÈ­]°æÇÕÀúÇØÁ¦.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • corrosion inhibitor
    ºÎ½Ä¹æÁöÁ¦(¡­ÛÁò­ð¥).
  • fertility inhibitor
    ¼öÁ¤¾ïÁ¦Á¦.
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ovulation inhibitor
    ¹è¶õ ÀúÇØÁ¦(ÛÉÕ°îÁúªð¥)
  • respiratory inhibitor
    È£Èí ÀúÇØÁ¦(îÁúªð¥)
  • reversible inhibitor
    °¡¿ª ÀúÇØÁ¦(îÁúªð¥)
  • soybean trypsin inhibitor
    ´ëµÎ(ÓÞÔç) Æ®¸³½Å ÀúÇØÁ¦(îÁúªð¥)
  • transition state inhibitor
    õÀÌ»óÅ ÀúÇØÁ¦(ôÃì¹ßÒ÷¾îÁúªð¥)
  • Trojan horse inhibitor
    Æ®·ÎÀ̸ñ¸¶(ÙÊØ©) ÀúÇØÁ¦(îÁúªð¥)
  • uncompetitive inhibitor
    ¹«°æÇÕ(ÙíÌæùê) ÀúÇØÁ¦(îÁúªð¥)
  • activating enzyme
    "ºÎȰȿ¼Ò (Ý·üÀý£áÈ), Ȱ¼ºÈ­È¿¼Ò (üÀàõûùý£áÈ)"
  • acyl activating enzyme
    ¾Æ½ÇºÎȰȿ¼Ò (Ý·üÀý£áÈ)
  • acyl enzyme
    ¾Æ½ÇÈ¿¼Ò(ý£áÈ)
  • acyl enzyme intermediates
    ¾Æ½ÇÈ¿¼Ò Áß°£Ã¼(ñéÊàô÷)
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò(îêëëý£áÈ)
  • alteration enzyme
    º¯ÇüÈ¿¼Ò(ܨúþý£áÈ)
  • ambiquitous enzyme
    ¾çÁ¸È¿¼Ò(å»ðíý£áÈ)
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
ACE Angiotensin Converting Enzyme
  = Kininase II
  = Dipeptidyl Carboxypepti...
ACE acetonitrile; acetylcholine esterase; acute cerebral encephalopathy; acute coronary event; adrenocor...
ACEDS angiotensin-converting enzyme dysfunction syndrome
AICE angiotensin I converting enzyme
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACEi Angiotensin I converting enzyme inhibition
ACE Angiotensin converting enzyme activity
CEI Converting enzyme inhibition
ECE ET converting enzyme
ECE Endothelin converting enzyme
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • enzyme activator
    È¿¼Ò Ȱ¼ºÁ¦
  • enzyme disorder
    È¿¼Ò Àå¾Ö
  • enzyme immunoassay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
    ¼Ò·®ÀÌ¶óµµ ±× Ȱ¼ºÀ» °ËÃâÇÒ ¼ö ÀÖ´Â °í°¨µµÀÇ È¿¼Ò¸¦ Ç¥½ÃÀÚ·Î Çϰí Ç׿ø ȤÀº Ç×ü, ³ª¾Æ°¡¼­´Â ƯÀÌÀûÀ¸·Î ¹ÝÀÀÇÏ´Â ¹°Áú, lectin, C1q µîÀ» È­ÇÐÀûÀ¸·Î °áÇÕ½ÃÄÑ, Ç׿ø ȤÀº Ç×ü µûÀ§¸¦ ÃøÁ¤ÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • enzyme labeled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • enzyme precursor
    È¿¼Ò Àü±¸Ã¼
  • enzyme-labelled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • enzyme-linked immunoadsorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • flavin enzyme
    Çöóºó È¿¼Ò
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ È¿¼Ò ¸é¿ªÇÐÀû ÃøÁ¤, ºÒ±ÕÀÏ È¿¼Ò ¸é¿ªÇÐÀû ÃøÁ¤¹ý
  • induced enzyme
    À¯µµ È¿¼Ò
    ±âÁú ¶Ç´Â ±×¿Í ±¸Á¶ÀûÀ¸·Î ¿¬°üµÈ, À¯µµ ¹°ÁúÀÇ Àڱؿ¡ ÀÇÇÏ¿© »ý¼ºµÈ È¿¼Ò.
  • lipolytic enzyme
    Áö¹æ ºÐÇØ È¿¼Ò
  • lysosomal enzyme
    ¸®¼ÒÁ» È¿¼Ò, ¿ëÇØ ¼Òü È¿¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
carbonic acid inhibitor <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma.
(27 Sep 1997)
carbonic anhydrase inhibitor <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma.
Examples include acetazolamide, dichlorphenamide and methazolamide.
(27 Sep 1997)
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
glucosidase inhibitor Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000)
medication, ace-inhibitor Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart.
(12 Dec 1998)
residual inhibitor A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off.
(05 Mar 2000)
respiratory inhibitor A compound that inhibits the respiratory chain.
Synonym: respiratory poison.
(05 Mar 2000)
cholinesterase inhibitor <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle.
Examples include pyridostigmine, ambenonium and neostigmine.
(15 Jan 1998)
monoamine oxidase inhibitor <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions.
Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine.
Acronym: MAOI
(26 Mar 1998)
complement cytolysis inhibitor <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge.
Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III.
(11 Jan 1998)
plasminogen activator inhibitor 1 <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
plasminogen activator inhibitor 2 <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
cyclooxygenase inhibitor <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
(08 Mar 2000)
protease inhibitor A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á